Table 3. Grade 3 and higher adverse events for all cycles in evaluable patients in the dose escalation phase.

Patient cohort	1	2	3	Total
Guadecitabine dose	20 mg/m2, day 1-5	20 mg/m2, day 1-5 + G-CSF	30 mg/m2, day 1-5 + G-CSF
n	4	8	5	17
Patients that experienced at least one AE graded 3 or above	4 (100%)	8 (100%)	5 (100%)	17 (100%)
Blood and lymphatic system disorders
Anaemia	1 (25.0%)	2 (25.0%)	2 (40.0%)	5 (29.4%)
Febrile neutropenia	1 (25.0%)	1 (12.5%)	0 (0.0%)	2 (11.8%)
Neutropenia	3 (75.0%)	5 (62.5%)	5 (100.0%)	13 (76.5%)
Leucopenia	1 (25.0%)	1 (12.5%)	3 (60.0%)	5 (29.4%)
Pancytopenia	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
Thrombocytopenia	4 (100.0%)	4 (50.0%)	3 (60.0%)	11 (64.7%)
Ear and labyrinth disorders
Hypoacusis	1 (25.0%)	0 (0.0%)	0 (0.0%)	1 (5.9%)
Tinnitus	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)
Gastrointestinal disorders
Diarrhoea	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)
Melaena	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
Nausea	1 (25.0%)	1 (12.5%)	0 (0.0%)	2 (11.8%)
Vomiting	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
General disorders and administration site conditions
Fatigue	1 (25.0%)	0 (0.0%)	0 (0.0%)	1 (5.9%)
Pyrexia	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)
Infections and infestations
Corona virus infection	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
Infection	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)
Pneumonia	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
Tooth Infection	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)
Urinary Tract Infection	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
Metabolism and nutrition disorders
Dehydration	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
Hypokalaemia	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)
Hypomagnesaemia	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)
Hyponatraemia	1 (25.0%)	0 (0.0%)	0 (0.0%)	1 (5.9%)
Renal and urinary disorders
Ureteric Obstruction	0 (0.0%)	1 (12.5%)	0 (0.0%)	1 (5.9%)
Vascular disorders
Embolism	1 (25.0%)	1 (12.5%)	0 (0.0%)	2 (11.8%)
Peripheral Ischaemia	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (5.9%)